JOHNSON & JOHNSON
JNJPharmaceutical Preparations(NJ)CIK: 200406
Income Statement
| Concept | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax | $85.2B | $80.0B | $78.7B | $82.6B | $82.1B |
| Cost of Goods and Services Sold | $26.6B | $24.6B | $23.4B | $28.4B | $27.6B |
| Gross Profit | $58.6B | $55.4B | $55.3B | $54.2B | $54.5B |
| Research and Development Expense | $483.0M | $0.00 | $0.00 | — | — |
| Selling, General and Administrative Expense | $21.5B | $20.2B | $20.1B | $22.1B | $22.2B |
| Operating Income (Loss) | — | — | — | — | — |
| Interest Expense | — | — | $183.0M | $201.0M | $318.0M |
| Other Nonoperating Income (Expense) | -$6.6B | -$810.0M | -$526.0M | -$2.9B | -$2.5B |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $15.1B | $19.4B | $19.2B | $16.5B | $17.3B |
| Income Tax Expense (Benefit) | $1.7B | $3.0B | $1.4B | $1.8B | $2.2B |
| Net Income (Loss) Attributable to Parent | $35.2B | $17.9B | $20.9B | $14.7B | $15.1B |
| Earnings Per Share, Basic | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 |
| Earnings Per Share, Diluted | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 |
Balance Sheet
| Concept | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Assets | $180.1B | $167.6B | $187.4B | $182.0B | $174.9B |
| Assets, Current | $55.9B | $53.5B | $55.3B | $61.0B | $51.2B |
| Cash and Cash Equivalents, at Carrying Value | $24.1B | $21.9B | $12.9B | $14.5B | $14.0B |
| Accounts Receivable, after Allowance for Credit Loss, Current | $14.8B | $14.9B | $14.0B | $15.3B | $13.6B |
| Inventory, Net | $12.4B | $11.2B | $10.3B | $10.4B | $9.3B |
| Liabilities | $108.6B | $98.8B | $110.6B | $108.0B | $111.6B |
| Liabilities, Current | $50.3B | $46.3B | $55.8B | $45.2B | $42.5B |
| Long-term Debt | $32.4B | $27.4B | $28.4B | $32.1B | $34.4B |
| Accounts Payable, Current | $10.3B | $9.6B | $9.9B | $11.1B | $9.5B |
| Weighted Average Number of Shares Outstanding, Basic | $2.5B | $2.6B | $2.6B | $2.6B | $2.6B |
Cash Flow Statement
| Concept | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Cash Provided by (Used in) Operating Activities | $22.8B | $21.2B | $23.4B | $23.5B | $23.4B |
| Net Cash Provided by (Used in) Investing Activities | $878.0M | -$12.4B | -$8.7B | -$20.8B | -$6.2B |
| Net Cash Provided by (Used in) Financing Activities | -$15.8B | -$8.9B | -$14.0B | -$6.1B | -$18.0B |
| Payments to Acquire Property, Plant, and Equipment | $4.5B | $4.0B | $3.7B | $3.3B | $3.5B |
| Payments for Repurchase of Common Stock | $5.1B | $6.0B | $3.5B | $3.2B | $6.7B |
Build with this data
Access SEC EDGAR data via REST API. Free tier available.
from sec_edgar import SecEdgar
api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)